have a question, issue or just some feedback for us? we're here for you.

what can we help you with?

let us know how we can help

DISCLAIMER

The information and materials accessed through or made available for use on any of our Sites, including, any information about diseases, conditions, treatments, or medicines, are for informational purposes only. The Content is not intended to be and is not a substitute for professional medical advice, diagnosis, or treatment, and your participation on our Sites does not create a healthcare professional-patient relationship. You should consult a doctor or other qualified health care professional regarding any questions you have about your health or before making any decisions related to your health or wellness. Call your doctor or 911 immediately if you think you may have a medical emergency.

compose your message

to*

from*

subject

message

message sent

email sent successfully

suggest a poll

you must have an account to suggest polls.

join now

You are receiving this because you have an account on www.oneGRAVESvoice.com
To unsubscribe from these emails, click here

Trusted Resources: News & Meetings

Latest announcements and gatherings

Clinical Trials And Research
Business
People
Spotlight
Happenings
Fundraising Events

Back to News & Meetings / Clinical Trials And Research

Teprotumumab Improves Short and Long-Term Clinical Outcomes in Thyroid Eye Disease

Most adults with thyroid eye disease receiving an infusion of teprotumumab every 3 weeks for a 24-week period had a reduction of at least 2 mm in proptosis, with a long-term response observed in 67% of participants, according to study data.

“These analyses provide insight into both the short-term and long-term efficacy and safety of teprotumumab and are clinically relevant as all objective signs and symptoms of thyroid eye disease, especially proptosis and diplopia, which can be resistant to medical therapy, were markedly and significantly improved with teprotumumab,” George J. Kahaly, MD, PhD, a professor of medicine, endocrinology and metabolism at Johannes Gutenberg University Medical Center in Mainz, Germany, and colleagues wrote in a study published in The Lancet Diabetes & Endocrinology.

Source: https://www.healio.com/news/endocrinology/20210423/teprotumumab-improves-short-and-longterm-clinical-outcomes-in-thyroid-eye-disease

Discuss in Social Wall

Twitter

Share to rareTeam

myBinder

send a message

send to:
subject:
message:

To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Trusted Resources Home

Evidence & Education

People & Places

News & Meetings

Videos & Visuals

Partner Pages

Teprotumumab Improves Short and Long-Term Clinical Outcomes in Thyroid Eye Disease

Related Content

Powered by

Trusted Resources Home

Evidence & Education

People & Places

Community Center

News & Meetings

Videos & Visuals

Partner Pages

Trusted Resources: News & Meetings

Latest announcements and gatherings

Teprotumumab Improves Short and Long-Term Clinical Outcomes in Thyroid Eye Disease

Related Content

Powered by